行情

VIVO

VIVO

美鼎生物
NASDAQ

实时行情|Nasdaq Last Sale

24.63
-0.04
-0.16%
盘后: 24.63 0 0.00% 16:41 05/16 EDT
开盘
24.57
昨收
24.67
最高
24.83
最低
24.04
成交量
20.88万
成交额
0
52周最高
28.72
52周最低
17.00
市值
10.73亿
市盈率(TTM)
17.42
分时
5日
1月
3月
1年
5年
Marijuana Stock Movers For May 9, 2022
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 9.00% at $1.09
Benzinga · 05/09 20:48
Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History
Benzinga · 05/06 19:10
Meridian Bioscience (VIVO) Q2 Earnings and Revenues Surpass Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 37.50% and 11.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 13:15
Meridian Bioscience: Q2 Earnings Insights
  Meridian Bioscience (NASDAQ:VIVO) reported its Q2 earnings results on Friday, May 6, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/06 13:08
BRIEF-Meridian Bioscience Reports Record Second Quarter Fiscal 2022 Operating Results
reuters.com · 05/06 12:22
Meridian Bioscience Q2 EPS $0.66 Beats $0.47 Estimate, Sales $111.23M Beat $99.54M Estimate
Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.47 by 40.43 percent. This is a 17.86 percent increase over earnings of $0.56 per share from
Benzinga · 05/06 12:19
-- Earnings Flash (VIVO) MERIDIAN BIOSCIENCE Reports Q2 EPS $0.66
MT Newswires · 05/06 08:09
Meridian Bioscience's Earnings: A Preview
Meridian Bioscience (NASDAQ:VIVO) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Meridian Bioscience will report an earnings per share (EPS) of $...
Benzinga · 05/05 17:22
更多
暂无数据
了解VIVO最新的财务预测,通过VIVO每股收益,每股净资产,每股现金流等数据分析美鼎生物近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

50.00%强力推荐
50.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测VIVO价格均价为30.00,最高价位30.00,最低价为30.00。
最高30.00
均价30.00
最低30.00
现价24.63
EPS
实际EPS
预期EPS
0.170.330.490.66
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
机构持股
总机构数: 278
机构持股: 4,841.01万
持股比例: 111.10%
总股本: 4,357.51万
类型机构数股数
增持
49
210.79万
建仓
27
193.00万
减持
67
293.95万
平仓
27
100.02万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
+0.39%
医疗设备和用品
-0.13%
高管信息
Chairman/Director
John McIlwraith
Chief Executive Officer/Director
John Kenny
Chief Financial Officer/Executive Vice President
Andrew Kitzmiller
Executive Vice President
Tony Serafini-Lamanna
Executive Vice President
Lourdes Weltzien
Chief Accounting Officer
Julie Smith
Independent Director
James Anderson
Independent Director
Anthony Bihl
Independent Director
Dwight Ellingwood
Independent Director
John Rice
Independent Director
Catherine Sazdanoff
Independent Director
Felicia Williams
暂无数据
暂无数据
VIVO 简况
Meridian Bioscience Inc是一家生命科学公司。该公司从事诊断检测试剂盒的开发、制造、销售和分销,主要针对某些胃肠道和呼吸道传染病以及血铅水平升高病症。该公司的分部包括诊断和生命科学。诊断分部业务包括在俄亥俄州辛辛那提、加拿大魁北克市以及以色列莫迪的传染病产品制造业务。该分部业务还包括马萨诸塞州比勒里卡的血液化学产品以及国内外诊断产品的销售和分销。生命科学分部包括在田纳西州孟菲斯、佛罗里达州博卡拉顿、英国伦敦和德国卢肯瓦尔德的制造业务,以及国内外散装抗原、抗体、聚合酶链反应(PCR)/定量PCR(qPCR)试剂、核苷酸和生物研究试剂的销售和分销。

微牛提供Meridian Bioscience, Inc.(NASDAQ-VIVO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的VIVO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易VIVO股票基本功能。